Exclusive video interview: David Wood demystifies the transhumanist agenda

As Longevity moves quickly into the mainstream there are terms and legacies that some use to challenge the sector’s validity: we explore what it means to be a transhumanist.

David Wood is on the Board of Directors of the Institute for Ethics and Emerging Technologies and as Chair of London Futurists, David has organised regular meetings in London since 2008 covering: futurist; transhumanist; techno-progressive; and singularitarian matters.

Longevity.Technology: Back in April, when we ran our digital conference Longevity 2020, David Wood was a key participant in the ask-me-anything sessions: his questions were on-point and his comments articulate:

In this exclusive video interview, we explore which technologies will have the greatest impact on human beings in the 21st century and NBIC interconnections:

  • Nanotech … control at the nanoscale – this domain will include quantum in the future;
  • Biotech … gene editing, epigenome, proteome and regenerative technologies;
  • Infotech … AI, biotech, and digital systems that move us closer to the Singularity;
  • Cognotech (Neurotech) … interconnections between neurons and digital tech, at this stage the least developed, but with potential to have the most profound impact.

David talks about Covid-19 and the crisis of mental health and how healthy aging is about individuals continuing to have a rich connection to society:

Phil Newman
Editor-in-Chief Phil has over 25 years of C-level management, marketing and business development expertise in Europe and North America. His creative background has helped him shape unconventional strategies for commercial growth - garnering both awards and investor ROI.

Phil has wide experience of technology transfer and the commercialisation of innovations from both private and institutional sources and this led to his interest in Longevity and the founding of Longevity.Technology.

Latest articles

Evidence for tenth hallmark of aging increases with new paper

Is ten the new nine? Additional research adds weight to the argument that extracellular matrix stiffening should be considered the tenth hallmark of aging. Since...

Help us help you: Longevity biotech survey

A new survey on translational processes and hurdles to clinical trials in Longevity biotech. We're working with two MDs: Oliver Zolman and Jian Fransen, on...

First Longevity announces first investors for current round

Some news of our own: European VC fund and a Longevity innovator participate in the First Longevity funding round. Last week we announced that Tom...

GDF15 protects from age‐related metabolic phenotypes

A recent study shows an important role for GDF15 in preventing aging-induced metabolic phenotypes by modulating systemic inflammatory responses in humans and mice. Dysfunction of...